En del af Watch Medier

MedWatchfredag3. februar 2023

  • Søg
  • Log ind
  • Medicinal & Biotek
  • Medico & Rehab
  • Laboratorie & Diagnostik
  • Høreapparater
  • Søg
  • Log ind
  • Seneste
  • Søg
  • Log ind
  • Medicinal & Biotek
  • Medico & Rehab
  • Laboratorie & Diagnostik
  • Høreapparater
  • Digital sundhed
  • Samfund
  • Mennesker
  • Sygdom & Sundhed
23.08.2013kl. 12.59

Novo in extensive management reshuffle

Novo Nordisk has had to make extensive managerial changes with new chiefs in the US, Europe and China.
Foto: Colourbox
by Stefan Singh Kailay

Two recent events have led to a veritable domino effect in the managerial level immediately below top group management in Novo Nordisk.

Martin Soeters is no longer head of Novo Nordisk’s European division, and Ron Christie is no longer in charge of the all-important Chinese division. Both of these highly experienced directors have chosen to retire, and the two empty chairs have led to an extensive managerial reshuffle in the Danish diabetes giant.

“Seeing as we, as far as possible, prefer to fill positions like these with skilled internal candidates, any new appointment or retirement will leave a gap, leading to a domino effect around the organisation,” head of Corporate Communications, Mike Rulis, tells Medwatch about the reshuffling, which took place over the summer.

Seasoned people

It means that Jesper Høiland is no longer in charge of what he himself has called the youth department of Novo Nordisk; International Operations. The former head of all markets outside of Europe, North America, China and Japan has become the new head of Novo Nordisk’s North American business.

“Jesper Høiland is one of our most seasoned people around the world. He has been in charge of what some would call our most complex region, i.e. International Operations, which includes more than 150 countries from all continents. Jesper has proved very adept at leading and ensuring growth. When you are able to run a region like IO, there is no doubt that you have what it takes to be in charge of a region like North America, where the US is the by far largest business area for Novo Nordisk,” Mike Rulis explains, adding:

“There might be just two countries in Jesper’s new region, but the US alone is so complex, with so many payers and structures, that Jesper will get the chance to use his experience of leading under complex conditions.”

East and West

The now former chief for Novo in North America, Jerzy Gruhn, has moved across the Atlantic and has been appointed head of Novo Nordisk’s European division. Jerzy Gruhn is of Polish descent, so the stage is set for a homecoming.

“Before he went to the US, he headed our Eastern European division where he gained experience with the business environment that has since come to characterize the Western and Southern European countries as well, that is, a very sharp focus on reducing drug prices and limit reimbursements for medicine. That baggage could turn out to be a huge advantage for him,” says Mike Rulis, who rebuts the notion that Jerzy Gruhn’s move across the Atlantic should be seen as a demotion.

“Not at all. The European market is a huge task. I think anyone operating on the European drug market today would agree with that.”

Meanwhile, Maziar Mike Doustdar, who previously headed one of the regions under International Operations, moves up the corporate ladder, as he takes over the empty chair left by Jesper Høiland at the head of the table for International Operations.

Finally, Christian Kanstrup goes from being head of Finance and IT in Japan to becoming the new chief of Novo Nordisk in China.

Related articles:

Novo Nordisk-director quits the company 

Novo and Coloplast among the world’s most innovative companies

This is why Novo is losing market shares

Novo wants to secure reputation through data access

Novo: All doubts have been erased

Novo Nordisk tops global top 25 of biotechs

Novo among the 100 most valuable companies in the world 

- translated by Martin Havtorn Petersen

Want to receive the latest news from Medwatch straight in your e-mail inbox? Sign up for our free english newsletter below.

Relaterede artikler:

  • Per Valstorp leaves Novo Nordisk to retire. | Foto: Novo Nordisk

    Novo Nordisk-director quits the company

    For abonnenter

  • Novo and Coloplast among the world’s most innovative companies

  • Foto: Colourbox

    This is why Novo is losing market shares

Tilmeld dig vores nyhedsbrev

Vær på forkant med udviklingen. Få den nyeste viden fra branchen med vores nyhedsbrev.

!
Nyhedsbrevsvilkår

Forsiden lige nu

Med lanceringen af en helt ny generation af katetre kan Coloplasts gamle udgaver være på vej til at blive afløst. | Foto: Coloplast/pr
Medico & Rehab

Coloplast lancerer kateter med ny teknologi

Coloplast forventer, at engangskateteret Luja med en helt ny teknologi skal give selskabet øgede markedsandele på kontinensmarkederne verden over.
  • Coloplast vil tage kvantespring i kernemarkeder med højteknologiske produkter

For abonnenter

John Haurum, bestyrelsesformand i Solid Therapeutics | Foto: John Haurum / Privat
Medicinal & Biotek

Navneskift skal skabe investorinteresse for kræftselskab

For abonnenter

Foto: Coloplast / Pr
Medico & Rehab

Bundlinjen skuffer trods ellers stærkt regnskab fra Coloplast

For abonnenter

Anders Kühnau, formand for Danske Regioner | Foto: Rikke Kjær Poulsen / Ritzau Scanpix
Medicinal & Biotek

Danske Regioner klar med anbefalinger til kortere sagsbehandlingstider i Medicinrådet

For abonnenter

Foto: Stine Tidsvilde
Medicinal & Biotek

Novo Nordisk vil fastholde medarbejdere med aktiegave til 35.000 kr

For abonnenter

Stifterne af medtech-virksomheden Ward 24/7, som sidste år fik en investering fra finske Innovestor, der er klar til at investere i flere danske virksomheder. Her ses Ward 24/7's adm. direktør Betina Langemark (i midten), flankeret af medstifterne Christian Meyhoff (tv.) og Eske Aasvang (th.) | Foto: Ward 24/7 / PR
Medicinal & Biotek

Finsk venturefond ser mod Danmark for investeringer i life science

Seneste nyt

  • Coloplast lancerer kateter med ny teknologi – 08.38
  • Bundlinjen skuffer trods ellers stærkt regnskab fra Coloplast – 07.44
  • Navneskift skal skabe investorinteresse for kræftselskab – 06.58
  • Finsk venturefond ser mod Danmark for investeringer i life science – 2. feb.
  • Danske Regioner klar med anbefalinger til kortere sagsbehandlingstider i Medicinrådet – 2. feb.
  • MSD tjener mere end ventet i fjerde kvartal – 2. feb.
  • Novo Nordisk vil fastholde medarbejdere med aktiegave til 35.000 kr – 2. feb.
  • Roche forudser mindre salg og indtjening fra coronamidler i 2023 – 2. feb.
  • Eli Lilly løfter forventningerne til 2023 – 2. feb.
  • Analytikere: Kerneforretningen driver Ambus organiske vækst – 2. feb.
  • Efter sløv start haler diabetestablet fra Novo Nordisk ind på topsællert – 2. feb.
  • Medicinrådet er stadig for langsomme til at vurdere ny medicin – 2. feb.
  • Dansk Erhverv har lavet en ny life science-politik: Vi kan nå endnu længere, hvis vi justerer rammevilkårerne – 2. feb.
  • Boehringer Ingelheim flytter dansk hovedkvarter til Islands Brygge – 2. feb.
  • Fluoguide skifter finansdirektør efter få måneder – 2. feb.
Flere nyheder

Job

  • Medical Advisor (Metabolism)

  • Senior Clinical Project Manager

  • Commercial Director

  • Application Manager

  • Erfaren Patentrådgiver

  • Sr. Director, Drug Safety Physician

  • Lead Data Architect

  • Clinical Operational Associate

  • Specialist til udbud på lægemidler til danske sygehuse

  • Head of Regulatory Affairs Danmark

  • Senior Health Economics and Outcomes Research (HEOR) Manager

  • Application Manager

  • Senior Regulatory Affairs Professional

  • Supply Chain Manager

  • Regulatory Affairs Professional

Se flere jobs

Watch Job

  • Scrum Master with a practical approach

  • Erfaren IT Supporter

  • Business Controller til DAHL Advokatpartnerselskab i Jylland

  • Tilbudschef - NCC Renovering Vest

  • Business Change Manager til implementering af fremtidens togs uddannelsesprojekter

Se flere jobs

Job

  • Medical Advisor (Metabolism)

  • Senior Clinical Project Manager

  • Commercial Director

  • Application Manager

  • Erfaren Patentrådgiver

  • Sr. Director, Drug Safety Physician

  • Lead Data Architect

  • Clinical Operational Associate

  • Specialist til udbud på lægemidler til danske sygehuse

  • Head of Regulatory Affairs Danmark

  • Senior Health Economics and Outcomes Research (HEOR) Manager

  • Application Manager

  • Senior Regulatory Affairs Professional

  • Supply Chain Manager

  • Regulatory Affairs Professional

Se flere jobs

Kolofon

MedWatch
Søg

Sektioner

  • Medicinal & Biotek
  • Medico & Rehab
  • Laboratorie & Diagnostik
  • Høreapparater
  • Digital sundhed
  • Samfund
  • Mennesker
  • Sygdom & Sundhed
  • Sitemap
  • RSS feeds

Redaktør

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tlf.: +45 3330 8387

Ansv. chefredaktør

Anders Heering

Udgiver

JP/Politikens Hus A/S

Annonceafdeling

annoncering@infowatch.dk

Tlf.: +45 7077 7441

Annoncering

Jobannoncering

job@infowatch.dk

Tlf.: +45 7077 7441

Job

Abonnement

Prøv MedWatch gratis eller få tilbud på et abonnement, der passer til lige netop dig eller din virksomhed.

medwatch@infowatch.dk

Tlf.: +45 7077 7441

Læs mere om abonnement her

Adresse

MedWatch

Rådhuspladsen 37

1785 København V

Tlf.: +45 3330 8370

Retningslinjer

  • Persondatapolitik

Copyright © MedWatch — Alt materiale på denne side er omfattet af gældende lov om ophavsret

Microsoft er i gang med at udfase Internet Explorer – det er vi derfor også.
Vi anbefaler en af følgende browsere for en bedre oplevelse. Klik på et af ikonerne for at downloade en ny browser.

Med venlig hilsen,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge